Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Type 2 Inflammation Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-4RA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL4R ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (native glycosylation). |
View IL4R Products |
| Gene Delivery | IL4R Promise-ORF / Lentivirus Full-length ORF for stable cell line construction (Ba/F3 or CHO-K1). |
View IL4R Products |
| Benchmark Ab | Anti-IL4R (Dupilumab Biosimilar Sequence) Recombinant human IgG4 positive control for blocking assays. |
View IL4R Products |
| Validator | IL4R siRNA Set For knockdown verification and specificity controls. |
View IL4R Products |
| Signaling Partner (IL-13 pathway) | IL13RA1 Essential co-receptor for IL-13 signaling; required for Type II heterodimer assembly assays. |
View IL13RA1 Products |
| Common Gamma Chain | IL2RG (CD132) Shared subunit for Type I IL-4R; critical for selectivity screening vs. IL-2/IL-7/IL-15 pathways. |
View IL2RG Products |
| Related Target (Upstream) | TSLP Upstream epithelial alarmin synergistic with IL-4/13 signaling. |
View TSLP Products |
| Related Target (Parallel) | IL-13 Parallel Th2 cytokine sharing the Type II IL-4 receptor complex. |
View IL-13 Products |
| Related Target (Type 2 Axis) | IL5 Parallel Th2 pathway cytokine; combination therapy and bispecific development potential. |
View IL5 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dual Cytokine (IL-4 & IL-13) Competitive Binding | ECD-Fc fusion preserves conformational epitopes for both Type I (IL-4) and Type II (IL-4/IL-13) receptor complexes; verified by SPR/BLI ready |
| Cross-species (Human/Cyno/Mouse) Efficacy Toxicity Bridge | Ortholog protein panel (>95% purity) with sequence-verified binding domains for GLP tox and mechanistic studies |
| Selectivity vs. IL-2R Gamma Family (IL2RG) | Purified IL2RG protein available for strict counter-screening to exclude off-target cytokine signaling |
| Heterodimer Assembly (IL4R+IL13RA1) | Co-expression systems and individually purified components for binary/ternary complex formation assays |
| Biosimilar Equivalence Testing | Clinical-grade Dupilumab sequence reference antibody with defined endotoxin specifications |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Biosimilars) included for direct comparative SPR |
| False Positives in cell assays | Validated siRNA included for specificity and knockdown checks |
Live IL-4RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance & Escape Mechanisms
- ➤ Recent Patent Filings (Biosimilars & Next-Gen)
Global Clinical Landscape & Future Outlook
The IL-4RA therapeutic landscape is dominated by the remarkable clinical success of Dupilumab (Dupixent), which established the target as a cornerstone for Type 2 inflammation management. As the first-generation monoclonal antibody approaches patent cliff (2029-2030 in key markets), the competitive intensity is bifurcating into two vectors: (1) a high-volume biosimilar race requiring rigorous analytical similarity packages, and (2) next-generation modalities including bispecific antibodies (IL-4/IL-13/IL-5 axes), oral small molecule inhibitors of the receptor or downstream signaling, and upstream pathway modulators (anti-TSLP, anti-OX40L) that may eventually compete for the same patient populations. The dual-cytokine (IL-4 and IL-13) blockade verification and selectivity screening against the common gamma chain shared with IL-2, IL-7, and IL-15 receptors have become critical assay requirements.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (incl. Biosimilar) | Sanofi, Regeneron, Sandoz, Biocon, Luye Pharma | Atopic Dermatitis, Asthma | SPR Affinity Matching (KD ±10%), CDR Sequence Verification, Cyno Cross-reactivity |
| Bispecific / Trispecific Antibody | Sanofi (SAR440340/GLP-1 combo), AstraZeneca, Connective players | Severe Type 2 Inflammation, Prurigo Nodularis | Dual-target Bridging Assay (need IL4R + IL5/IL13 heterodimer validation) |
| Oral Small Molecule | Big Pharma (undisclosed) | Mild-Moderate Atopic Dermatitis | Cell-based potency (Lentivirus-stable lines), Selectivity panel (JAK vs IL4R) |
| Upstream Inhibitor (TSLP/OX40L) | Amgen/AZ (Tezepelumab), Roche (Amlitelimab) | Broad Type 2 Inflammation | Pathway crossover studies (IL4R+TSLPR co-expression assays) |
Target Biology & Key Mutations
IL-4RA (also known as CD124, IL4R) is a transmembrane receptor critical for Th2 immune responses. Its extracellular domain contains Fibronectin type-III repeats (UniProt P24394 domain). Several clinically relevant polymorphisms have been identified: rs1805010 (two distinct amino acid substitutions, UniProt VAR_059302 and VAR_059303) and rs1 (a probable risk factor for atopic asthma and cedar pollen sensitization, UniProt VAR_008034). These mutations highlight the importance of personalized assay panels for patient stratification in IL-4RA-targeted therapies.
Future Directions & TarMart Empowerment
TarMart provides high-purity, HEK293-expressed IL4R ECD-Fc fusion protein with native glycosylation (sequence-verified, >95% purity, endotoxin <1 EU/µg), along with a comprehensive reagent portfolio including Dupilumab biosimilar reference antibody, IL4R siRNA, and ortholog proteins (human, cyno, mouse) for preclinical and biosimilar development. Our cross-reactivity kits and heterodimer assembly tools enable robust differentiation of next-generation IL-4RA therapeutics.